News | January 22, 2014

BeneChill Receives Frost & Sullivan Award for Intranasal Cooling System for Therapeutic Hypothermia

BeneChill RhinoChill Therapeutic Hypothermia Cath Lab Intranasal Cooling System
January 22, 2014 — BeneChill Inc. received the 2014 Frost & Sullivan Award for Technology Innovation Leadership for its RhinoChill intranasal cooling system. 
 
BeneChill's RhinoChill is a nasopharyngeal device that can induce and sustain therapeutic hypothermia during active resuscitation after cardiac arrest. The system is noninvasive, time critical and can be used by nonmedical personnel to prevent brain damage associated with cardiac arrest.
 
RhinoChill is portable and battery-operated with a control unit, coolant bottle and a transnasal cooling catheter to facilitate use outside of hospital settings. The technology enables brain cooling close to the time of cerebral ischemic events, including in the absence of blood circulation. RhinoChill's technology initially targets brain cooling and then body cooling during cardiac arrest and after resuscitation.
 
The technology maintains therapeutic hypothermia brain temperatures by deploying two 10 cm long nasal catheter prongs that spray a mist of liquid proprietary coolant into the nasal cavity. The sprayed coolant evaporates on contact with the internal nares of the skull and facilitates rapid heat transfer. Lungs expel the coolant as inert and nontoxic gas.
 
RhinoChill’s operating input voltage is 10 to 18 V DC, and the control unit draws little current to enable battery operation. Its dimensions are 39 x 26 x 16 cm and it weighs approximately 5 to 9 kg. The system's components can connect in 30 to 60 seconds and can deploy immediately. RhinoChill features an auto shut off that is responsive to pressure in the nasal cavity beyond a threshold.
 
BeneChill plans to expand the technology to other fields such as traumatic brain injury, neuroradiology, neurosurgery and cardiac surgery.
 
Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impacts both the functionality and the customer value of the new products and applications. The award lauds the high R&D spend towards innovation, its relevance to the industry and the positive impact on brand perception.
 
For more information: www.benechill.com, www.frost.com

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Overlay Init